Bio News
Eli Lilly has received approval from the U.S. Food and Drug Administration (FDA) for the combination of the oral selective estrogen receptor degrader (SERD) Inluriyo and the CDK4/6 inhibitor Verzenio.
In the phase 3 trial, the median progression-free survival with the combination was 11.1 months, longer than the 5.5 months observed with Inluriyo monotherapy.
Jake Van Naarden, president of Lilly Oncology, predicted that most patients would choose the combination over monotherapy.
BIOBOOK TEAM
biobookmedia@biobook.co.krAspen Neuroscience and Bambusa Plan U.S. IPOs; Developers of Parkinson’s and Bispecific Antibody Therapies
St. Jude Identifies Cell Marker for High-Risk Neuroblastoma
University of Texas at Austin Develops Flexible Electrode for Recording Brain Waves for a Month Without Shaving Hair
Revolution Medicines Shares Fall 6.3% on Concerns About RASONK’s KRAS Subgroup
GSK Adopts Chai Discovery AI Model After Wet-Lab Validation
Teva Wins FDA Approval for Long-Acting Olanzapine Beltruzza for Schizophrenia
Peptone nears end of two-year Lilly technology evaluation…follow-on deal could be pivotal
HLB Pharmaceutical Completes 60.8 Billion Won Rights Offering, Bets on New Hyangnam Plant as Management Participation Grows
Song Young-sook sells 86 billion won stake; buyer is daughter’s one-person company — Is a second round of Hanmi control battle looming?
